Nanexa AB (publ) (NANEXA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to this live report with Nanexa, the drug delivery company. You who are watching can ask questions in the live chat, something we see that some of you have already been able to do. There will be many questions today. I greet the CEO, David Westberg. Welcome. Thank you very much. You've had a lot to say in the last few days, I think. Yes, that's true. The days have been intense. Until last night, when we released the announcement about Applied Materials. We'll get back to that, I'm sure, in the questions. We can rest there. It has been intensive with our studies as well. Yes, it has been a very intensive quarter. How would you say, what has characterized this quarter? To start with, on the financial side, we had the emissions that we did in January, which was in the planning. So there was a lot to do with that, and I'm very happy that we put it in. It feels fantastic, because now we have funding one year ahead, so the whole Q1 next year. That's definitely the case. We also got some additional funding from Applied, which makes it look a bit better. The size is 7.5 million. Yes, 7.5 million. The dollar exchange rate has dropped, so that's a bit of a shame. But apart from that, we started the fourth cohort in the NEXT22 study. And you have seen that I have reported a little bit about it here now. We have generally gotten very good results from it. In terms of safety, it is still fantastic. It is quite remarkable that we do not get these normal side-reactions, and so on, even though we have such a high dose. So that's good. Very limited injection side-reactions, and that's also good. So it's a study that, and I'm very happy that we were able to add that cohort, the dose cohort, to the study that we did last year. So that's good, it has been intensive there. We are...